PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
11291827-5	2001	This Phase 1 study in patients with solid tumors was carried out to determine a maximum tolerated daily oral dose (MTD) for CI-994 administered on a chronic basis.	tacedinaline	124-130	metallothionein 1E	Homo sapiens	115-118
12700284-4	2003	In assays of isolated enzymes, CI-994 inhibited HDAC-1 and HDAC-2 in a concentration-dependent fashion but had no effect on the activity of the prototypical histone acetyltransferase GCN5.	tacedinaline	31-37	histone deacetylase 1	Homo sapiens	48-54
12700284-4	2003	In assays of isolated enzymes, CI-994 inhibited HDAC-1 and HDAC-2 in a concentration-dependent fashion but had no effect on the activity of the prototypical histone acetyltransferase GCN5.	tacedinaline	31-37	histone deacetylase 2	Homo sapiens	59-65
32811822-7	2020	Administration of CI-994 increased BDNF expression after TBI.	tacedinaline	18-24	brain derived neurotrophic factor	Mus musculus	35-39
34690667-7	2021	Biochemical analyses showed increased acetylation of histone marks H3K27ac and H3K18ac at the dopamine 2 receptor (D2R) gene (Drd2) promoter and increased expression of the Drd2 mRNA and D2R protein in the striatum of aged mice after administration of CI-994 at 20 mg/kg.	tacedinaline	252-258	dopamine receptor D2	Mus musculus	94-113
34690667-7	2021	Biochemical analyses showed increased acetylation of histone marks H3K27ac and H3K18ac at the dopamine 2 receptor (D2R) gene (Drd2) promoter and increased expression of the Drd2 mRNA and D2R protein in the striatum of aged mice after administration of CI-994 at 20 mg/kg.	tacedinaline	252-258	dopamine receptor D2	Mus musculus	115-118
34690667-7	2021	Biochemical analyses showed increased acetylation of histone marks H3K27ac and H3K18ac at the dopamine 2 receptor (D2R) gene (Drd2) promoter and increased expression of the Drd2 mRNA and D2R protein in the striatum of aged mice after administration of CI-994 at 20 mg/kg.	tacedinaline	252-258	dopamine receptor D2	Mus musculus	126-130
34690667-7	2021	Biochemical analyses showed increased acetylation of histone marks H3K27ac and H3K18ac at the dopamine 2 receptor (D2R) gene (Drd2) promoter and increased expression of the Drd2 mRNA and D2R protein in the striatum of aged mice after administration of CI-994 at 20 mg/kg.	tacedinaline	252-258	dopamine receptor D2	Mus musculus	173-177
34690667-7	2021	Biochemical analyses showed increased acetylation of histone marks H3K27ac and H3K18ac at the dopamine 2 receptor (D2R) gene (Drd2) promoter and increased expression of the Drd2 mRNA and D2R protein in the striatum of aged mice after administration of CI-994 at 20 mg/kg.	tacedinaline	252-258	dopamine receptor D2	Mus musculus	187-190
34367950-2	2021	Based on previous studies showing high histone deacetylase 1 (HDAC1) expression in AT/RT, the HDAC1 inhibitor CI-994 was used as a novel treatment strategy in this study.	tacedinaline	110-116	histone deacetylase 1	Homo sapiens	39-60
34367950-2	2021	Based on previous studies showing high histone deacetylase 1 (HDAC1) expression in AT/RT, the HDAC1 inhibitor CI-994 was used as a novel treatment strategy in this study.	tacedinaline	110-116	histone deacetylase 1	Homo sapiens	62-67
34367950-2	2021	Based on previous studies showing high histone deacetylase 1 (HDAC1) expression in AT/RT, the HDAC1 inhibitor CI-994 was used as a novel treatment strategy in this study.	tacedinaline	110-116	histone deacetylase 1	Homo sapiens	94-99
32950972-11	2020	In IL-1beta-treated PHCs, CI994 promoted AGGRECAN expression and suppressed MMP-13 expression, abolishing the effect of IL-1beta on PHCs.	tacedinaline	26-31	interleukin 1 alpha	Homo sapiens	3-11
32950972-11	2020	In IL-1beta-treated PHCs, CI994 promoted AGGRECAN expression and suppressed MMP-13 expression, abolishing the effect of IL-1beta on PHCs.	tacedinaline	26-31	aggrecan	Homo sapiens	41-49
32950972-11	2020	In IL-1beta-treated PHCs, CI994 promoted AGGRECAN expression and suppressed MMP-13 expression, abolishing the effect of IL-1beta on PHCs.	tacedinaline	26-31	matrix metallopeptidase 13	Homo sapiens	76-82
32950972-11	2020	In IL-1beta-treated PHCs, CI994 promoted AGGRECAN expression and suppressed MMP-13 expression, abolishing the effect of IL-1beta on PHCs.	tacedinaline	26-31	interleukin 1 alpha	Homo sapiens	120-128
34798471-0	2022	Epigenetic therapy combination of UNC0638 and CI-994 suppresses breast cancer via epigenetic remodeling of BIRC5 and GADD45A.	tacedinaline	46-52	baculoviral IAP repeat containing 5	Homo sapiens	107-112
34798471-0	2022	Epigenetic therapy combination of UNC0638 and CI-994 suppresses breast cancer via epigenetic remodeling of BIRC5 and GADD45A.	tacedinaline	46-52	growth arrest and DNA damage inducible alpha	Homo sapiens	117-124
34798471-2	2022	This study aimed to demonstrate the clinical significance of euchromatic histone lysine methyltransferase 2 (EHMT2), histone deacetylase 1 (HDAC1) and HDAC2 in BC, to evaluate the antitumor effectiveness of a combination of the selective inhibitors UNC0638 and CI-994 (U+C), and to clarify the underlying mechanisms.	tacedinaline	261-267	euchromatic histone lysine methyltransferase 2	Homo sapiens	61-107
34120025-5	2021	Molecular Docking studies of compounds 5e and 5f reveal a similar binding mode of interactions as CI994 at the HDAC3 active site.	tacedinaline	98-103	histone deacetylase 3	Mus musculus	111-116
32599645-4	2020	Here, we describe that TW9, a newly generated adduct of the BET inhibitor (+)-JQ1 and class I HDAC inhibitor CI994, is a potent dual inhibitor simultaneously targeting BET and HDAC proteins.	tacedinaline	109-114	histone deacetylase 9	Homo sapiens	94-98
32599645-4	2020	Here, we describe that TW9, a newly generated adduct of the BET inhibitor (+)-JQ1 and class I HDAC inhibitor CI994, is a potent dual inhibitor simultaneously targeting BET and HDAC proteins.	tacedinaline	109-114	delta/notch like EGF repeat containing	Homo sapiens	168-171
32599645-4	2020	Here, we describe that TW9, a newly generated adduct of the BET inhibitor (+)-JQ1 and class I HDAC inhibitor CI994, is a potent dual inhibitor simultaneously targeting BET and HDAC proteins.	tacedinaline	109-114	histone deacetylase 9	Homo sapiens	176-180
33102692-5	2020	Transcription factor (TF) profiler and promoter binding array reveals 22 TFs differentially activated by CI-994, of which FOXA1 is identified as a unique and positive regulator of NIS.	tacedinaline	105-111	forkhead box A1	Homo sapiens	122-127
32889570-2	2020	Male Wistar rats weighing 210+-10 g were randomly divided into 3 groups: control, 3-day hindlimb suspension, and 3-day hindlimb suspension and injection of HDAC1 inhibitor CI-994 (1 mg/kg/day).	tacedinaline	172-178	histone deacetylase 1	Rattus norvegicus	156-161
32889570-5	2020	Inhibition of HDAC1 by CI-994 during 3-day hindlimb suspension prevented the decrease in titin content and development of atrophy in rat soleus muscle.	tacedinaline	23-29	histone deacetylase 1	Rattus norvegicus	14-19
32889570-5	2020	Inhibition of HDAC1 by CI-994 during 3-day hindlimb suspension prevented the decrease in titin content and development of atrophy in rat soleus muscle.	tacedinaline	23-29	titin	Rattus norvegicus	89-94
31906036-8	2019	Moreover, we found that therapeutic targeting HADC3 by tacedinaline or NF-kappaB by ML029 is likely able to overcome the TMZ resistance in GBM cells with H2AFJ upregulation.	tacedinaline	55-67	H2A.J histone	Homo sapiens	154-159
30796167-7	2019	Results: Treatment with 5-fluorouracil alone or in combination with decitabine or tacedinaline reduced tumor cell viability and induced apoptosis, enhanced radiosensitivity in BON1 and QGP1 cells, induced SSTR2 expression, and resulted in increased radioligand binding of 68Ga-DOTATOC in NET cells.	tacedinaline	82-94	somatostatin receptor 2	Homo sapiens	205-210
30796167-8	2019	Conclusion: This preclinical study demonstrated that 5-fluorouracil alone or in combination with decitabine or tacedinaline caused radiosensitization of tumor cells, upregulation of SSTR2 expression in tumor cells, and increased radioligand binding of 68Ga-DOTATOC to these tumor cells.	tacedinaline	111-123	somatostatin receptor 2	Homo sapiens	182-187
31311969-5	2019	CI-994 treatment prevented HS-induced increase in HDAC1 nuclear content.	tacedinaline	0-6	histone deacetylase 1	Rattus norvegicus	50-55
31311969-7	2019	CI-994 administration resulted in an attenuation of HS-mediated increase in MAFbx and ubiquitin expression levels but did not affect MuRF-1 expression.	tacedinaline	0-6	F-box protein 32	Rattus norvegicus	76-81
23810801-3	2013	To begin to better understand the role of the class I HDAC subtypes HDAC 1, 2 and 3 in modulating brain activity, we utilized two benzamide inhibitors from the literature, compound 60 (Cpd-60) and CI-994 which selectively inhibit HDAC 1 and 2 or HDACs 1, 2 and 3, respectively.	tacedinaline	197-203	histone deacetylase 1	Rattus norvegicus	68-83
30682334-0	2019	Histone deacetylase inhibitor CI-994 inhibits osteoclastogenesis via suppressing NF-kappaB and the downstream c-Fos/NFATc1 signaling pathways.	tacedinaline	30-36	FBJ osteosarcoma oncogene	Mus musculus	110-115
30682334-0	2019	Histone deacetylase inhibitor CI-994 inhibits osteoclastogenesis via suppressing NF-kappaB and the downstream c-Fos/NFATc1 signaling pathways.	tacedinaline	30-36	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	116-122
30682334-1	2019	[4-(acetylamino)-N-(2-amino-phenyl) benzamide] (CI-994) is a histone deacetylase 1-3 specific inhibitor that has been shown to indirectly increase the production of Dickkopf-1, which is an inhibitor of osteoclastic development.	tacedinaline	0-46	histone deacetylase 1	Mus musculus	61-82
30682334-1	2019	[4-(acetylamino)-N-(2-amino-phenyl) benzamide] (CI-994) is a histone deacetylase 1-3 specific inhibitor that has been shown to indirectly increase the production of Dickkopf-1, which is an inhibitor of osteoclastic development.	tacedinaline	0-46	dickkopf WNT signaling pathway inhibitor 1	Mus musculus	165-175
30682334-1	2019	[4-(acetylamino)-N-(2-amino-phenyl) benzamide] (CI-994) is a histone deacetylase 1-3 specific inhibitor that has been shown to indirectly increase the production of Dickkopf-1, which is an inhibitor of osteoclastic development.	tacedinaline	48-54	histone deacetylase 1	Mus musculus	61-82
30682334-1	2019	[4-(acetylamino)-N-(2-amino-phenyl) benzamide] (CI-994) is a histone deacetylase 1-3 specific inhibitor that has been shown to indirectly increase the production of Dickkopf-1, which is an inhibitor of osteoclastic development.	tacedinaline	48-54	dickkopf WNT signaling pathway inhibitor 1	Mus musculus	165-175
30682334-2	2019	However, whether CI-994 has an influence on receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoclastogenesis is still unclear; in our study, this mechanism was investigated.	tacedinaline	17-23	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	44-95
30682334-2	2019	However, whether CI-994 has an influence on receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoclastogenesis is still unclear; in our study, this mechanism was investigated.	tacedinaline	17-23	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	97-102
30682334-6	2019	Moreover, CI-994 inhibited the expression of osteoclast-related genes, including ACP5, CTSK, NFATc1, c-Fos, DC-STAMP and V-ATPase-d2.	tacedinaline	10-16	acid phosphatase 5, tartrate resistant	Mus musculus	81-85
30682334-6	2019	Moreover, CI-994 inhibited the expression of osteoclast-related genes, including ACP5, CTSK, NFATc1, c-Fos, DC-STAMP and V-ATPase-d2.	tacedinaline	10-16	cathepsin K	Mus musculus	87-91
30682334-6	2019	Moreover, CI-994 inhibited the expression of osteoclast-related genes, including ACP5, CTSK, NFATc1, c-Fos, DC-STAMP and V-ATPase-d2.	tacedinaline	10-16	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	93-99
30682334-6	2019	Moreover, CI-994 inhibited the expression of osteoclast-related genes, including ACP5, CTSK, NFATc1, c-Fos, DC-STAMP and V-ATPase-d2.	tacedinaline	10-16	FBJ osteosarcoma oncogene	Mus musculus	101-106
30682334-7	2019	Furthermore, CI-994 suppressed the phosphorylation of IkappaBalpha and p65 and the expression of downstream c-Fos and NFATc1.	tacedinaline	13-19	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	54-66
30682334-7	2019	Furthermore, CI-994 suppressed the phosphorylation of IkappaBalpha and p65 and the expression of downstream c-Fos and NFATc1.	tacedinaline	13-19	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	71-74
30682334-7	2019	Furthermore, CI-994 suppressed the phosphorylation of IkappaBalpha and p65 and the expression of downstream c-Fos and NFATc1.	tacedinaline	13-19	FBJ osteosarcoma oncogene	Mus musculus	108-113
30682334-7	2019	Furthermore, CI-994 suppressed the phosphorylation of IkappaBalpha and p65 and the expression of downstream c-Fos and NFATc1.	tacedinaline	13-19	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	118-124
30682334-9	2019	In conclusion, CI-994 inhibited osteoclastogenesis by suppressing NF-kappaB and the downstream c-Fos/NFATc1 signaling pathway.	tacedinaline	15-21	FBJ osteosarcoma oncogene	Mus musculus	95-100
30682334-9	2019	In conclusion, CI-994 inhibited osteoclastogenesis by suppressing NF-kappaB and the downstream c-Fos/NFATc1 signaling pathway.	tacedinaline	15-21	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	101-107
25827403-2	2015	An innovative aspect of this drug delivery particle lies in the NP conjugation of a histone deacetylase (HDAC) inhibitor, CI-994 (Tacedinaline), introduced with a clickable acid-responsive prodrug during monomer synthesis, prior to polymerization.	tacedinaline	122-128	histone deacetylase 9	Homo sapiens	84-103
25827403-2	2015	An innovative aspect of this drug delivery particle lies in the NP conjugation of a histone deacetylase (HDAC) inhibitor, CI-994 (Tacedinaline), introduced with a clickable acid-responsive prodrug during monomer synthesis, prior to polymerization.	tacedinaline	122-128	histone deacetylase 9	Homo sapiens	105-109
25827403-2	2015	An innovative aspect of this drug delivery particle lies in the NP conjugation of a histone deacetylase (HDAC) inhibitor, CI-994 (Tacedinaline), introduced with a clickable acid-responsive prodrug during monomer synthesis, prior to polymerization.	tacedinaline	130-142	histone deacetylase 9	Homo sapiens	84-103
25827403-2	2015	An innovative aspect of this drug delivery particle lies in the NP conjugation of a histone deacetylase (HDAC) inhibitor, CI-994 (Tacedinaline), introduced with a clickable acid-responsive prodrug during monomer synthesis, prior to polymerization.	tacedinaline	130-142	histone deacetylase 9	Homo sapiens	105-109
23810801-3	2013	To begin to better understand the role of the class I HDAC subtypes HDAC 1, 2 and 3 in modulating brain activity, we utilized two benzamide inhibitors from the literature, compound 60 (Cpd-60) and CI-994 which selectively inhibit HDAC 1 and 2 or HDACs 1, 2 and 3, respectively.	tacedinaline	197-203	histone deacetylase 1	Rattus norvegicus	230-242
23810801-3	2013	To begin to better understand the role of the class I HDAC subtypes HDAC 1, 2 and 3 in modulating brain activity, we utilized two benzamide inhibitors from the literature, compound 60 (Cpd-60) and CI-994 which selectively inhibit HDAC 1 and 2 or HDACs 1, 2 and 3, respectively.	tacedinaline	197-203	histone deacetylase 1	Rattus norvegicus	246-262
21771726-9	2011	Thus, efficient restoration of caspase-8 expression in SCLC cells is achieved when a combination of DNMT and HDAC inhibitors is used, suggesting a combination of decitabine and VPA or CI-994 as a potential treatment for sensitization of SCLC cells lacking caspase-8 to TRAIL.	tacedinaline	184-190	caspase 8	Homo sapiens	31-40
21771726-5	2011	Among all studied HDAC inhibitors, valproic acid (VPA) and CI-994 showed prolonged effects on histone acetylation, while combination with decitabine produced the most prominent effects on caspase-8 re-expression.	tacedinaline	59-65	histone deacetylase 9	Homo sapiens	18-22
21771726-9	2011	Thus, efficient restoration of caspase-8 expression in SCLC cells is achieved when a combination of DNMT and HDAC inhibitors is used, suggesting a combination of decitabine and VPA or CI-994 as a potential treatment for sensitization of SCLC cells lacking caspase-8 to TRAIL.	tacedinaline	184-190	caspase 8	Homo sapiens	256-265
21771726-9	2011	Thus, efficient restoration of caspase-8 expression in SCLC cells is achieved when a combination of DNMT and HDAC inhibitors is used, suggesting a combination of decitabine and VPA or CI-994 as a potential treatment for sensitization of SCLC cells lacking caspase-8 to TRAIL.	tacedinaline	184-190	TNF superfamily member 10	Homo sapiens	269-274
18424067-6	2008	HDAC inhibitors, under clinical evaluation in the treatment of NSCLC patients, are pivanex, CI-994, vorinostat, and LBH589.	tacedinaline	92-98	histone deacetylase 9	Homo sapiens	0-4
17455259-4	2007	In contrast, the benzamides CI994, MS275 and MGCD0103 are more selective, potent inhibitors of at least HDAC1 and HDAC3.	tacedinaline	28-33	histone deacetylase 1	Homo sapiens	104-109
17455259-4	2007	In contrast, the benzamides CI994, MS275 and MGCD0103 are more selective, potent inhibitors of at least HDAC1 and HDAC3.	tacedinaline	28-33	histone deacetylase 3	Homo sapiens	114-119